Waypoint Bio
Summary active Updated Jun 6, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
About
Waypoint Bio is an AI-native biotech company developing next-generation CAR T cell therapies for solid tumors, using a platform that integrates artificial intelligence, computer vision, and spatial pooled screening 1. The company’s lead program, WAY-103, is an in vivo CAR T asset paired with a proprietary next-generation lentiviral vector, with clinical entry in China expected in late 2026 12. Dr. Patrick Kaifosh, previously co-founder and Chief Scientific Officer of neuro-AI startup CTRL-Labs and Senior Director at Meta’s Reality Labs, recently joined as CTO 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-01 | Series A | $20M | Amplify Partners | General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, Hummingbird Ventures 12 |
What Investors Say
No independently sourced investor quotes beyond press release boilerplate are available at this time. Amplify Partners’ Elliot Hershberg joined the Waypoint Bio board of directors as part of the round 1.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
“Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic,” BusinessWire, June 1, 2026. Accessed June 2026. https://www.businesswire.com/news/home/20260601266582/en/Waypoint-Bio-Raises-$20M-Series-A-Led-by-Amplify-Partners-to-Advance-AI-Designed-Cell-Therapies-Toward-the-Clinic↩↩↩↩↩
-
“Venture Capital & Startup Funding Roundup, June 1, 2026,” Tech Startups, June 1, 2026. Accessed June 2026. https://techstartups.com/2026/06/01/venture-capital-startup-funding-roundup-june-1-2026/↩↩